Kitty Victoria, MD
Medical Oncology · Kealakekua, HINPI 1871917633
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,868 of the $2,592 with a category attached, or 72.1%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.0%. Reporting peaked in 2023 at $1,057 and has fallen 72.5% since, to $291 in 2025.
Across 103 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$519
- Tempus AI, Inc$302
- E.r. Squibb & Sons, L.L.C.$220
- Amgen$205
- Pfizer$182
- Johnson & Johnson$163
- plus $1K from 23 others
What the payments were for
- Food & beverage$1,86872%
- Education$72428%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $519 |
| Tempus AI, Inc | 5 | $302 |
| E.r. Squibb & Sons, L.L.C. | 16 | $220 |
| Amgen | 4 | $205 |
| Pfizer | 12 | $182 |
| Johnson & Johnson | 6 | $163 |
| AstraZeneca(2 entities) | 8 | $136 |
| Merck | 5 | $95 |
| AVEO Pharmaceuticals, Inc. | 1 | $85 |
| Genentech USA, Inc. | 3 | $66 |
| Exelixis Inc. | 3 | $65 |
| Acrotech Biopharma Inc. | 4 | $55 |
| Myovant Sciences Inc. | 3 | $55 |
| Sobi, Inc | 2 | $54 |
| Sanofi | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Eisai Inc. | 2 | $42 |
| Array Biopharma Inc | 2 | $36 |
| Novartis | 1 | $29 |
| Lilly USA, LLC | 1 | $26 |
| Incyte Corporation | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIMMUNE$100
How this compares
Too few medical oncology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 13 | $363 |
| Anastrozole | 16 | $297 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Kealakekua
- Naoto UenoHonolulu$288K
- Jami FukuiHonolulu$17K
- Shaun DoneganHonolulu$17K
- Clayton ChanHonolulu$2K
- Clayton ChongHonolulu$2K
- Charles MillerHonolulu$326
- Reuben GuerreroHonolulu$35
- Kevin LohHonolulu$31
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.